Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Bases de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Transfus Apher Sci ; 49(3): 528-32, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-23541712

RESUMO

BACKGROUND: The dedicated devices for blood irradiation are available only at a few centers in developing countries thus the irradiation remains a service with limited availability due to prohibitive cost. OBJECTIVE: To implement a blood irradiation program at our center using linear accelerator. MATERIALS AND METHODS: The study is performed detailing the specific operational and quality assurance measures employed in providing a blood component-irradiation service at tertiary care hospital. X-rays generated from linear accelerator were used to irradiate the blood components. To facilitate and standardize the blood component irradiation, a blood irradiator box was designed and fabricated in acrylic. Using Elekta Precise Linear Accelerator, a dose of 25 Gy was delivered at the centre of the irradiation box. Standardization was done using five units of blood obtained from healthy voluntary blood donors. Each unit was divided to two parts. One aliquot was subjected to irradiation. Biochemical and hematological parameters were analyzed on various days of storage. Cost incurred was analyzed. RESULTS: Progressive increase in plasma hemoglobin, potassium and lactate dehydrogenase was noted in the irradiated units but all the parameters were within the acceptable range indicating the suitability of the product for transfusion. The irradiation process was completed in less than 30 min. Validation of the radiation dose done using TLD showed less than ± 3% variation. CONCLUSION: This study shows that that the blood component irradiation is within the scope of most of the hospitals in developing countries even in the absence of dedicated blood irradiators at affordable cost.


Assuntos
Transfusão de Componentes Sanguíneos/métodos , Transfusão de Sangue/métodos , Aceleradores de Partículas/instrumentação , Transfusão de Componentes Sanguíneos/economia , Transfusão de Componentes Sanguíneos/instrumentação , Transfusão de Sangue/economia , Transfusão de Sangue/instrumentação , Análise Custo-Benefício , Humanos , Aceleradores de Partículas/economia
2.
J Cancer Res Ther ; 6(1): 36-40, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-20479545

RESUMO

BACKGROUND: Non Hodgkin's Lymphoma (NHL) cure rates are increasing and morbidities are decreasing, with more active pharmacological agents and technological advancements. In spite of this, India is still battling with the prejudices of an economically and educationally impoverished patient base. METHODS AND RESULTS: We analyzed NHL cases from 2000 to 2006 using data from case sheets. Of 303 cases, only 100 patients had complete workup and received some form of treatment. For 203 patients, reasons for non-compliance were: financial constraint (119), distance from center (38), inability of physician to provide guarantees of cure (13), poor prognosis/fear of recurrence (28)), preferences for alternate medicine (5). Most common investigations that could not be afforded for staging were whole body CT scans and bone marrow aspiration and biopsy. Thirteen patients were in stage III and 53 in Stage IV. The most common regimen was CHOP (Cyclophosphamide, Adriamycin, Vincristine, Prednisolone). Forty-five patients did not complete six courses of CHOP and 35 patients had significant delay. Reasons for delay were intermittent availability of cash (35), intolerable toxicities (30), absence of supportive care (21), given-up attitudes (17). Eighty-three patients suffered Grade III/IV debilitating toxicities. Overall survival at five years was 50%. CONCLUSIONS: NHL in India is no different from the developed world. However, there are disparities in survivorship and outcomes, due to un-affordability and attitudes of the patients. Therefore, we suggest the development of Community Health Insurance Schemes (CHIs), with the hospital as the nodal center to address the above mentioned issues.


Assuntos
Conhecimentos, Atitudes e Prática em Saúde , Disparidades em Assistência à Saúde , Linfoma não Hodgkin/tratamento farmacológico , Cooperação do Paciente/estatística & dados numéricos , Protocolos de Quimioterapia Combinada Antineoplásica/economia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Ciclofosfamida/economia , Ciclofosfamida/uso terapêutico , Países em Desenvolvimento , Doxorrubicina/economia , Doxorrubicina/uso terapêutico , Epirubicina , Etoposídeo , Disparidades em Assistência à Saúde/economia , Disparidades em Assistência à Saúde/estatística & dados numéricos , Humanos , Ifosfamida , Índia , Leucovorina , Linfoma não Hodgkin/diagnóstico , Linfoma não Hodgkin/economia , Metotrexato , Prednisona/economia , Prednisona/uso terapêutico , Procarbazina , Vincristina/economia , Vincristina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA